Clonal hematopoiesis

Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)

By MedXY 12/03/2025

A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discrimination (C=0.80) and reclassification.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Clinical Updates news

Personalized Low-Dose Aspirin Use for Cancer Prevention in Older Adults

By MedXY 09/25/2025

A secondary analysis of the ASPREE trial reveals low-dose aspirin’s heterogeneous effects on cancer prevention in older adults, highlighting clonal hematopoiesis of indeterminate potential (CHIP) as a key predictor for benefit.

Cardiology news Specialties

Clonal Hematopoiesis as a Novel Risk Factor for Myocarditis and Pericarditis: Insights from the UK Biobank

By MedXY 08/31/2025

Clonal hematopoiesis of indeterminate potential (CHIP) is linked to a significantly increased risk of new-onset myocarditis and pericarditis, especially involving DNMT3A and TET2 mutations, highlighting a potential target for preventing inflammatory heart diseases.

Allergy & Immunology Hematology-Oncology Specialties

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

By MedXY 08/29/2025

Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for prophylactic strategies.